ArticleERJ open research2025

Cystic fibrosis transmembrane conductance regulator therapy with elexacaftor/tezacaftor/ivacaftor reduces detection of hallmark cystic fibrosis pathogens in Europe: progress made but no time to slow down.

Katharina Schütz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.